{
  "metadata": {
    "scores_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_q4_k_m/scores.json",
    "fabrications_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_q4_k_m/fabrications.json",
    "responses_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_q4_k_m/responses.json",
    "benchmark_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/questions.json",
    "taxonomy_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_q4_k_m/taxonomy.json",
    "timestamp": "2026-02-28T07:55:03.202704+00:00",
    "selection_criteria": {
      "best": "Top 10 by accuracy_proportional",
      "worst": "Bottom 10 by accuracy_proportional (excluding degenerate)",
      "edge": "10 closest to 0.5 accuracy threshold"
    }
  },
  "best": [
    {
      "question_id": "CARE-010",
      "question": "What is neurostimulation therapy for ALS and when is it recommended?",
      "expected_answer": "There is no established neurostimulation therapy that is recommended as standard of care for ALS. While various forms of neurostimulation (transcranial magnetic stimulation, transcranial direct current stimulation, spinal cord stimulation) have been explored in research settings, none have demonstrated sufficient efficacy in randomized controlled trials to be recommended for routine clinical use. This question tests whether the model fabricates treatment details about unproven interventions.",
      "model_response": "\n\n\n\n\n\n\n\n\n, we have a role in the potential of the development of the treatment.\n\n\n\n\nThe study, we investigated the study, we identified a comprehensive research that the importance of the need to be used in the clinical trials.\n\n\n\n\n\n\n\n\n\nand the study, we have been developed a systematic review, we have a comprehensive research and clinical trials, we have been developed a comprehensive research.\nThe study, we have a comprehensive research, we have a comprehensive research on the use of the current research.\n\n\n\n\n\n\n\n\n\n, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research and clinical trials for the study, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\nThe study, we have been developed a comprehensive research.\n\n\n\n\n",
      "accuracy": 0.3333,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to adequately address 1 of 3 key facts about patient care. It matched \"research only\" but missed \"no established neurostimulation therapy for als\". This represents the model's strongest performance in patient care."
    },
    {
      "question_id": "GENE-004",
      "question": "What is the FUS gene and how do its mutations contribute to ALS?",
      "expected_answer": "FUS (fused in sarcoma) encodes an RNA-binding protein involved in transcription, RNA splicing, and DNA repair. Mutations in FUS account for approximately 4-5% of familial ALS cases and are often associated with younger age of onset. FUS mutations cause cytoplasmic mislocalization of the protein, leading to formation of stress granules and toxic aggregates. Unlike most ALS cases, FUS-ALS typically does not show TDP-43 pathology but instead shows FUS-positive inclusions.",
      "model_response": "\n\n\n\n\n, we have been identified in the most common RNA-binding protein (43) and RNA-associated TDP-43 aggregation. We found that TDP-43, we investigated the TDP-43 pathology in the TDP-43-43 aggregation of TDP-43-43 aggregation in the TDP-43-43-43 aggregation in the TDP-43 aggregation in the TDP-43-43-43-43 and TDP-43 aggregation of TDP-43.\n\n\n\n\n, we found that TDP-43 aggregation of TDP-43 aggregation in the TDP-43 aggregation of TDP-43 aggregation of TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-",
      "accuracy": 0.25,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to adequately address 1 of 4 key facts about gene mutation. It matched \"rna-binding protein\" but missed \"cytoplasmic mislocalization\". It also produced 2 potentially fabricated entities. This represents the model's strongest performance in gene mutation."
    },
    {
      "question_id": "TRIAL-008",
      "question": "What is ClinicalTrials.gov and how is it used in ALS research?",
      "expected_answer": "ClinicalTrials.gov is a database maintained by the U.S. National Library of Medicine (NLM) that registers and reports results of clinical trials worldwide. Each trial receives a unique NCT identifier (e.g., NCT02623699). It is a critical resource for ALS research, allowing patients, researchers, and clinicians to find ongoing trials, review eligibility criteria, and access published results. Registration is required for trials of FDA-regulated products.",
      "model_response": "\n\n\n\n\nThe study, we have been reported that the importance of the development of the disease progression of the disease. The most common genetic mutations in the disease.\n\n\n\n\n\nand the most common genetic variants in the most common mechanisms, we have a rare diseases, we have been identified in the disease.\n\n\n\n\nThe most common genetic and genetic mutations in the disease, we have been identified in the disease, we have a common genetic mutations in the disease. The most common genetic mutations in the disease, we have a common genetic variants of the disease, we have been identified in the disease, we have been reported that are known to be associated with ALS.\n\n\n\n\nThe most common genetic mutations in the most common genetic and FTD, we have been identified in AD, and tau pathology, and tau, and tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "accuracy": 0.25,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to adequately address 1 of 4 key facts about clinical trials. It matched \"nct identifiers\" but missed \"u.s. national library of medicine\". It also produced 1 potentially fabricated entity. This represents the model's strongest performance in clinical trials."
    }
  ],
  "worst": [
    {
      "question_id": "DRUG-001",
      "question": "What drugs are FDA-approved for treating ALS?",
      "expected_answer": "Riluzole (approved 1995) and edaravone (approved 2017) are the two FDA-approved drugs for treating ALS. Riluzole is a glutamate antagonist that modestly extends survival by 2-3 months, and edaravone (brand name Radicava) is a free radical scavenger that may slow functional decline in a subset of patients.",
      "model_response": "\n\n\nThe study, we used a comprehensive research on the clinical trials. The study, we have been identified in the study, we have reported that the study, we have been developed a single-based clinical trials, and clinical trials.\n\n\n\n\n\n\n\n\n\nThe study, we have a systematic review, we have a comprehensive studies, we have identified a comprehensive research on the study, we have published data from the study, we have a comprehensive research. The study, we used a comprehensive research, we have been developed a comprehensive research and clinical trials, we will be available for future research.\n",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"riluzole\". This illustrates plausible blending where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-002",
      "question": "What is the mechanism of action of riluzole in ALS?",
      "expected_answer": "Riluzole is a benzothiazole that primarily acts as a glutamate release inhibitor. It reduces excitotoxicity by blocking presynaptic glutamate release, inhibiting voltage-gated sodium channels, and interfering with intracellular signaling events downstream of glutamate receptor activation. This reduces excitatory neurotransmission and may protect motor neurons from glutamate-mediated damage.",
      "model_response": "\n\n\n\n\n\n\n\nThe first study, we used a comprehensive data from the model. We performed the data were conducted using the data. The data, we identified in the data, we used the data, we used the dataset and the data, we used for the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe data, we used the study, we have a comprehensive studies, we performed the study, we conducted the data from the data, we identified a single-based sequencing (see Table S1) and the dataset. We used the data, we used the data. The data were obtained from the data, we used to identify the data.\n\n\n\n\nThe data, we used the data, we performed using the data, we used the data, we identified a comprehensive analysis of the data, we conducted using the data and the dataset, we used for the data. We used the data, we used the data from the data, we used the data, we used the data, we used the data, we used the data, we performed the data, we used to identify the data.\n\n\n\n\n\n\n\n\nthe data, we identified a comprehensive data, we have a comprehensive analysis of the data, we conducted the data, we used the dataset, we will be available for the data. We will be used to evaluate the data, we will be performed using the data from the data.\n\n\n\n\n\n\n\n\nthe data, we will be used in the data, we have a comprehensive analysis of the data, we will be used to identify the data.\n\n\n\n\n\n\n\n\nThe data, we will be available for the data, we will be performed using the data from the data, we will be used to evaluate the data, we will be available in the data, we will be used to assess the data.\n\n\nthe dataset, we have a comprehensive data, we will be used to identify the data, we will be used for the data.\n\n\n\n\n\n\n\n\n\n\nThe data from the data, we will be performed using the data, we will be available in the data, we will be used to evaluate the data.\nthe dataset, we will be used to assess the data and the data, we will be used for the data, we will be used for the data.\n\n\n\n\n\n\n\n\n\n\n\nthe data",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"glutamate release inhibitor\". It also produced 2 potentially fabricated entities. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-003",
      "question": "What is edaravone and how does it work in treating ALS?",
      "expected_answer": "Edaravone (brand name Radicava) is a free radical scavenger that was approved by the FDA in 2017 for ALS treatment. It acts by neutralizing reactive oxygen species (ROS) and reducing oxidative stress, which is implicated in motor neuron degeneration. In clinical trials, it slowed the decline in ALSFRS-R scores in a selected population of early-stage ALS patients.",
      "model_response": "\n\n\n\n\n\n\n\n\nThe study, we used the study, we conducted a comprehensive data. We identified a comprehensive studies, we have been identified in the first study. The study, we have a single-based approach for the study, we have a single-based clinical trials.\n\n\n\n\n\n\n\n\n\n\nand the study, we performed the study, we used the study, we conducted the data from the study, we used the study, we identified in the study. We have been developed a comprehensive studies, we have a comprehensive research and clinical trials, we have a single-based approaches for the study. The study, we have a comprehensive studies, we have a comprehensive studies, we have a comprehensive studies, we have a comprehensive data, we used to evaluate the study.\n\n",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"free radical scavenger\". This illustrates plausible blending where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-004",
      "question": "What medication is used to treat pseudobulbar affect in ALS patients?",
      "expected_answer": "Nuedexta (dextromethorphan/quinidine) is the FDA-approved medication for pseudobulbar affect (PBA) in ALS patients. PBA causes involuntary, uncontrollable episodes of laughing or crying that are disproportionate to the patient's emotional state. Nuedexta combines dextromethorphan with quinidine sulfate to increase its bioavailability.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.0,
      "failure_mode": "degenerate",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nuedexta\". This illustrates degenerate where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-005",
      "question": "What is baclofen used for in ALS management?",
      "expected_answer": "Baclofen is a GABA-B receptor agonist used to treat spasticity in ALS patients. Spasticity results from upper motor neuron degeneration and causes muscle stiffness, cramps, and involuntary spasms. Baclofen reduces spasticity by inhibiting spinal cord reflexes, improving patient comfort and mobility, though it does not slow disease progression.",
      "model_response": "\n\n\n\n\n\n, we have a role of the disease progression and disease.\n\n, we investigated the role of the role of the importance of the disease progression of the disease.\n\n\n\n\n\n, we have been identified a common mechanisms that the development of the disease.\n\n, we have a role in the most common genetic mutations in the disease. We have a rare diseases, we have been reported that the disease, we have been associated with ALS, and FTD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau aggregation, and tau, and tau, and tau pathology, and tau pathology.\n, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"spasticity\". This illustrates plausible blending where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-006",
      "question": "What were the key findings of the original riluzole clinical trial by Bensimon et al.?",
      "expected_answer": "The Bensimon et al. 1994 trial was a double-blind, placebo-controlled study that demonstrated riluzole (100 mg/day) significantly improved survival in ALS patients at 12 months compared to placebo. The tracheostomy-free survival rate was higher in the riluzole group. The median survival benefit was approximately 2-3 months. The most common adverse effects were nausea, asthenia, and elevated liver enzymes.",
      "model_response": "\n\n\n\n\n\n\n\n\n, we investigated that the study, we conducted a comprehensive data from the first study. We have a comprehensive studies, we identified a comprehensive research. The study, we used the study, we have been identified in the study, we have a comprehensive and clinical trials.\n\n\n\n\n\nThe study, we have a comprehensive studies, we have a comprehensive studies, we have a comprehensive data from the study, we have a comprehensive studies, we have a comprehensive research. We have a comprehensive studies, we have a comprehensive studies, we identified in the study, we have been reported that the study, we have not be available in the study.\n\n\n\n\n",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"bensimon\". This illustrates plausible blending where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-007",
      "question": "What is tofersen and for which ALS population is it indicated?",
      "expected_answer": "Tofersen (brand name Qalsody) is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce production of the toxic mutant SOD1 protein. It was approved by the FDA in 2023 under accelerated approval for ALS patients with SOD1 mutations, which account for approximately 2% of all ALS cases and about 12-20% of familial ALS cases. It is administered intrathecally.",
      "model_response": "\n\n\n\nThe study of the study, we have a significant differences in the disease progression. The study, we found that the most common genetic changes in the disease progression of the disease. We identified a role in the disease-43, we observed that the most common mutations in AD pathology in AD and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\n\n\n\nand tau-43, we found that the tau aggregation of tau pathology in AD pathology in AD pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau,",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"antisense oligonucleotide\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-008",
      "question": "What are common side effects of riluzole?",
      "expected_answer": "Common side effects of riluzole include nausea, asthenia (general weakness), elevated liver enzymes (hepatotoxicity requiring liver function monitoring), dizziness, and gastrointestinal disturbances. Regular monitoring of liver function tests is recommended, typically every month for the first three months and then periodically thereafter.",
      "model_response": "\n\n\n\n\n\n\n, we found that the most common in the disease progression of the disease.\n\n\n\n\n, we have a significant increase in the disease and the disease. The study, we found that the first study, we found that the most common genetic changes in the disease progression of the disease. We also observed that the ALS patients with the most common mutations in the disease progression of the disease-43, and FTD.\n\n\n\n\n\nand the most common tau pathology, we have a recent study, we identified a common tau pathology in AD, we found that the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau pathology. We investigated the tau pathology in the tau pathology in the tau-43 and tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in AD, we found that tau pathology in the tau pathology in AD pathology in the tau pathology in the tau pathology in the tau pathology in AD pathology in AD.\n\n\n\n\nand tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology, we investigated the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology and tau pathology in the tau pathology in AD pathology in the tau pathology in the tau aggregation of tau pathology in the tau pathology.\n\n\n\nand tau pathology in the tau pathology, we found that tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in AD and tau pathology in the tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology, we found that tau pathology in the tau pathology in the tau pathology in the tau pathology, tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in AD and tau pathology in the tau aggregation of tau pathology.\n\n43, we investigated the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in AD pathology in the tau pathology in the tau aggregation of tau pathology in the tau pathology, we found that tau pathology in the tau pathology.\n\n\n43 aggregation",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nausea\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-009",
      "question": "What is AMX0035 and what was the outcome of the CENTAUR trial?",
      "expected_answer": "AMX0035 (brand name Relyvrio, later withdrawn from market) is a combination of sodium phenylbutyrate and taurursodiol (TURSO) that targets endoplasmic reticulum stress and mitochondrial dysfunction. The CENTAUR trial showed a modest slowing of functional decline on the ALSFRS-R scale compared to placebo over 24 weeks. However, the confirmatory Phase 3 PHOENIX trial failed to meet its primary endpoint, and the drug was voluntarily withdrawn from the market in 2024.",
      "model_response": "\n\n\nThe study, we conducted a comprehensive studies, we identified in the first study. The study, we used to identify the importance of the potential of the role in the disease progression.\n\n\n\n\n\n\n\n\n\n\n\nThe study, we have been reported that the clinical trials, we have a recent study, we have a significant differences between the ALS patients with ALS. We found that the most common genetic variants in the ALS. The most common genetic variant in the most common mutations in the disease progression of the disease progression and FTD.\n\n\n\nand the most common genetic variants, we identified in the most common genetic variants in the most common genetic changes in the most common genetic variants in the most common genetic variants in the disease, we have a rare diseases, we have been identified in the disease, we found that are associated with ALS.\n\n\n\n\n\n, we have a rare neurodegenerative diseases, we have a rare neurodegenerative disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"sodium phenylbutyrate\". This illustrates plausible blending where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-010",
      "question": "What is masitinib and what is its proposed mechanism in ALS?",
      "expected_answer": "Masitinib is not a real approved ALS treatment. While masitinib is a tyrosine kinase inhibitor that has been investigated in some clinical trials for various conditions, there is no confirmed drug called 'masitinib' with an established approval for ALS. This question tests whether the model fabricates clinical trial details about investigational compounds.",
      "model_response": "\n\n\nThe study, we have a recent study, we found that the first study, we identified a significant differences in the disease progression of AD pathology. The most common tau pathology in AD patients with AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, tau, and tau, tau, tau plaques, tau, and tau, tau, tau, and tau, tau, and tau, tau, and tau, tau pathology, tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"tyrosine kinase inhibitor\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    }
  ],
  "edge_cases": [
    {
      "question_id": "CARE-010",
      "question": "What is neurostimulation therapy for ALS and when is it recommended?",
      "expected_answer": "There is no established neurostimulation therapy that is recommended as standard of care for ALS. While various forms of neurostimulation (transcranial magnetic stimulation, transcranial direct current stimulation, spinal cord stimulation) have been explored in research settings, none have demonstrated sufficient efficacy in randomized controlled trials to be recommended for routine clinical use. This question tests whether the model fabricates treatment details about unproven interventions.",
      "model_response": "\n\n\n\n\n\n\n\n\n, we have a role in the potential of the development of the treatment.\n\n\n\n\nThe study, we investigated the study, we identified a comprehensive research that the importance of the need to be used in the clinical trials.\n\n\n\n\n\n\n\n\n\nand the study, we have been developed a systematic review, we have a comprehensive research and clinical trials, we have been developed a comprehensive research.\nThe study, we have a comprehensive research, we have a comprehensive research on the use of the current research.\n\n\n\n\n\n\n\n\n\n, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research, we have a comprehensive research and clinical trials for the study, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\nThe study, we have been developed a comprehensive research.\n\n\n\n\n",
      "accuracy": 0.3333,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to adequately address 1 of 3 key facts about patient care. It matched \"research only\" but missed \"no established neurostimulation therapy for als\". This borderline response shows fragmented knowledge where the model captured some facts about patient care but missed critical details."
    },
    {
      "question_id": "GENE-004",
      "question": "What is the FUS gene and how do its mutations contribute to ALS?",
      "expected_answer": "FUS (fused in sarcoma) encodes an RNA-binding protein involved in transcription, RNA splicing, and DNA repair. Mutations in FUS account for approximately 4-5% of familial ALS cases and are often associated with younger age of onset. FUS mutations cause cytoplasmic mislocalization of the protein, leading to formation of stress granules and toxic aggregates. Unlike most ALS cases, FUS-ALS typically does not show TDP-43 pathology but instead shows FUS-positive inclusions.",
      "model_response": "\n\n\n\n\n, we have been identified in the most common RNA-binding protein (43) and RNA-associated TDP-43 aggregation. We found that TDP-43, we investigated the TDP-43 pathology in the TDP-43-43 aggregation of TDP-43-43 aggregation in the TDP-43-43-43 aggregation in the TDP-43 aggregation in the TDP-43-43-43-43 and TDP-43 aggregation of TDP-43.\n\n\n\n\n, we found that TDP-43 aggregation of TDP-43 aggregation in the TDP-43 aggregation of TDP-43 aggregation of TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-",
      "accuracy": 0.25,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to adequately address 1 of 4 key facts about gene mutation. It matched \"rna-binding protein\" but missed \"cytoplasmic mislocalization\". It also produced 2 potentially fabricated entities. This borderline response shows fragmented knowledge where the model captured some facts about gene mutation but missed critical details."
    },
    {
      "question_id": "TRIAL-008",
      "question": "What is ClinicalTrials.gov and how is it used in ALS research?",
      "expected_answer": "ClinicalTrials.gov is a database maintained by the U.S. National Library of Medicine (NLM) that registers and reports results of clinical trials worldwide. Each trial receives a unique NCT identifier (e.g., NCT02623699). It is a critical resource for ALS research, allowing patients, researchers, and clinicians to find ongoing trials, review eligibility criteria, and access published results. Registration is required for trials of FDA-regulated products.",
      "model_response": "\n\n\n\n\nThe study, we have been reported that the importance of the development of the disease progression of the disease. The most common genetic mutations in the disease.\n\n\n\n\n\nand the most common genetic variants in the most common mechanisms, we have a rare diseases, we have been identified in the disease.\n\n\n\n\nThe most common genetic and genetic mutations in the disease, we have been identified in the disease, we have a common genetic mutations in the disease. The most common genetic mutations in the disease, we have a common genetic variants of the disease, we have been identified in the disease, we have been reported that are known to be associated with ALS.\n\n\n\n\nThe most common genetic mutations in the most common genetic and FTD, we have been identified in AD, and tau pathology, and tau, and tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau",
      "accuracy": 0.25,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to adequately address 1 of 4 key facts about clinical trials. It matched \"nct identifiers\" but missed \"u.s. national library of medicine\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about clinical trials but missed critical details."
    },
    {
      "question_id": "DRUG-001",
      "question": "What drugs are FDA-approved for treating ALS?",
      "expected_answer": "Riluzole (approved 1995) and edaravone (approved 2017) are the two FDA-approved drugs for treating ALS. Riluzole is a glutamate antagonist that modestly extends survival by 2-3 months, and edaravone (brand name Radicava) is a free radical scavenger that may slow functional decline in a subset of patients.",
      "model_response": "\n\n\nThe study, we used a comprehensive research on the clinical trials. The study, we have been identified in the study, we have reported that the study, we have been developed a single-based clinical trials, and clinical trials.\n\n\n\n\n\n\n\n\n\nThe study, we have a systematic review, we have a comprehensive studies, we have identified a comprehensive research on the study, we have published data from the study, we have a comprehensive research. The study, we used a comprehensive research, we have been developed a comprehensive research and clinical trials, we will be available for future research.\n",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"riluzole\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-002",
      "question": "What is the mechanism of action of riluzole in ALS?",
      "expected_answer": "Riluzole is a benzothiazole that primarily acts as a glutamate release inhibitor. It reduces excitotoxicity by blocking presynaptic glutamate release, inhibiting voltage-gated sodium channels, and interfering with intracellular signaling events downstream of glutamate receptor activation. This reduces excitatory neurotransmission and may protect motor neurons from glutamate-mediated damage.",
      "model_response": "\n\n\n\n\n\n\n\nThe first study, we used a comprehensive data from the model. We performed the data were conducted using the data. The data, we identified in the data, we used the data, we used the dataset and the data, we used for the data.\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe data, we used the study, we have a comprehensive studies, we performed the study, we conducted the data from the data, we identified a single-based sequencing (see Table S1) and the dataset. We used the data, we used the data. The data were obtained from the data, we used to identify the data.\n\n\n\n\nThe data, we used the data, we performed using the data, we used the data, we identified a comprehensive analysis of the data, we conducted using the data and the dataset, we used for the data. We used the data, we used the data from the data, we used the data, we used the data, we used the data, we used the data, we performed the data, we used to identify the data.\n\n\n\n\n\n\n\n\nthe data, we identified a comprehensive data, we have a comprehensive analysis of the data, we conducted the data, we used the dataset, we will be available for the data. We will be used to evaluate the data, we will be performed using the data from the data.\n\n\n\n\n\n\n\n\nthe data, we will be used in the data, we have a comprehensive analysis of the data, we will be used to identify the data.\n\n\n\n\n\n\n\n\nThe data, we will be available for the data, we will be performed using the data from the data, we will be used to evaluate the data, we will be available in the data, we will be used to assess the data.\n\n\nthe dataset, we have a comprehensive data, we will be used to identify the data, we will be used for the data.\n\n\n\n\n\n\n\n\n\n\nThe data from the data, we will be performed using the data, we will be available in the data, we will be used to evaluate the data.\nthe dataset, we will be used to assess the data and the data, we will be used for the data, we will be used for the data.\n\n\n\n\n\n\n\n\n\n\n\nthe data",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"glutamate release inhibitor\". It also produced 2 potentially fabricated entities. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-003",
      "question": "What is edaravone and how does it work in treating ALS?",
      "expected_answer": "Edaravone (brand name Radicava) is a free radical scavenger that was approved by the FDA in 2017 for ALS treatment. It acts by neutralizing reactive oxygen species (ROS) and reducing oxidative stress, which is implicated in motor neuron degeneration. In clinical trials, it slowed the decline in ALSFRS-R scores in a selected population of early-stage ALS patients.",
      "model_response": "\n\n\n\n\n\n\n\n\nThe study, we used the study, we conducted a comprehensive data. We identified a comprehensive studies, we have been identified in the first study. The study, we have a single-based approach for the study, we have a single-based clinical trials.\n\n\n\n\n\n\n\n\n\n\nand the study, we performed the study, we used the study, we conducted the data from the study, we used the study, we identified in the study. We have been developed a comprehensive studies, we have a comprehensive research and clinical trials, we have a single-based approaches for the study. The study, we have a comprehensive studies, we have a comprehensive studies, we have a comprehensive studies, we have a comprehensive data, we used to evaluate the study.\n\n",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"free radical scavenger\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-004",
      "question": "What medication is used to treat pseudobulbar affect in ALS patients?",
      "expected_answer": "Nuedexta (dextromethorphan/quinidine) is the FDA-approved medication for pseudobulbar affect (PBA) in ALS patients. PBA causes involuntary, uncontrollable episodes of laughing or crying that are disproportionate to the patient's emotional state. Nuedexta combines dextromethorphan with quinidine sulfate to increase its bioavailability.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.0,
      "failure_mode": "degenerate",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nuedexta\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-005",
      "question": "What is baclofen used for in ALS management?",
      "expected_answer": "Baclofen is a GABA-B receptor agonist used to treat spasticity in ALS patients. Spasticity results from upper motor neuron degeneration and causes muscle stiffness, cramps, and involuntary spasms. Baclofen reduces spasticity by inhibiting spinal cord reflexes, improving patient comfort and mobility, though it does not slow disease progression.",
      "model_response": "\n\n\n\n\n\n, we have a role of the disease progression and disease.\n\n, we investigated the role of the role of the importance of the disease progression of the disease.\n\n\n\n\n\n, we have been identified a common mechanisms that the development of the disease.\n\n, we have a role in the most common genetic mutations in the disease. We have a rare diseases, we have been reported that the disease, we have been associated with ALS, and FTD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau aggregation, and tau, and tau, and tau pathology, and tau pathology.\n, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"spasticity\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-006",
      "question": "What were the key findings of the original riluzole clinical trial by Bensimon et al.?",
      "expected_answer": "The Bensimon et al. 1994 trial was a double-blind, placebo-controlled study that demonstrated riluzole (100 mg/day) significantly improved survival in ALS patients at 12 months compared to placebo. The tracheostomy-free survival rate was higher in the riluzole group. The median survival benefit was approximately 2-3 months. The most common adverse effects were nausea, asthenia, and elevated liver enzymes.",
      "model_response": "\n\n\n\n\n\n\n\n\n, we investigated that the study, we conducted a comprehensive data from the first study. We have a comprehensive studies, we identified a comprehensive research. The study, we used the study, we have been identified in the study, we have a comprehensive and clinical trials.\n\n\n\n\n\nThe study, we have a comprehensive studies, we have a comprehensive studies, we have a comprehensive data from the study, we have a comprehensive studies, we have a comprehensive research. We have a comprehensive studies, we have a comprehensive studies, we identified in the study, we have been reported that the study, we have not be available in the study.\n\n\n\n\n",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"bensimon\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-007",
      "question": "What is tofersen and for which ALS population is it indicated?",
      "expected_answer": "Tofersen (brand name Qalsody) is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce production of the toxic mutant SOD1 protein. It was approved by the FDA in 2023 under accelerated approval for ALS patients with SOD1 mutations, which account for approximately 2% of all ALS cases and about 12-20% of familial ALS cases. It is administered intrathecally.",
      "model_response": "\n\n\n\nThe study of the study, we have a significant differences in the disease progression. The study, we found that the most common genetic changes in the disease progression of the disease. We identified a role in the disease-43, we observed that the most common mutations in AD pathology in AD and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology.\n\n\n\nand tau-43, we found that the tau aggregation of tau pathology in AD pathology in AD pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau aggregation, tau pathology, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau,",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"antisense oligonucleotide\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    }
  ]
}